# IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

> **NCT00747604** · — · TERMINATED · sponsor: **Ipsen** · enrollment: 1378 (actual)

## Conditions studied

- Primary Insulin-like Growth Factor-1 Deficiency

## Interventions

- **BIOLOGICAL:** mecasermin [rDNA origin] injection

## Key facts

- **NCT ID:** NCT00747604
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 1378 (ACTUAL)
- **Why stopped:** Shortage of Increlex supply
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747604, "IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00747604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*